Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1 , Pages 38-48 , January 2008

Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease⁎

  • Harald Hampel

      Affiliations

    • Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience (TCIN), Trinity College Dublin, Trinity Centre for Health Sciences, The Adelaide and Meath Hospital Incorporating The National Children’s Hospital (AMiNCH), Dublin, Ireland
    • Department of Psychiatry, Alzheimer Memorial Center, Ludwig-Maximilian University, Munich, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +353-1 896 3706; Fax: +353-1 896 1313.
    • ,
  • Katharina Bürger

      Affiliations

    • Department of Psychiatry, Alzheimer Memorial Center, Ludwig-Maximilian University, Munich, Germany
    • ,
  • Stefan J. Teipel

      Affiliations

    • Department of Psychiatry, Alzheimer Memorial Center, Ludwig-Maximilian University, Munich, Germany
    • ,
  • Arun L.W. Bokde

      Affiliations

    • Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience (TCIN), Trinity College Dublin, Trinity Centre for Health Sciences, The Adelaide and Meath Hospital Incorporating The National Children’s Hospital (AMiNCH), Dublin, Ireland
    • Department of Psychiatry, Alzheimer Memorial Center, Ludwig-Maximilian University, Munich, Germany
    • ,
  • Henrik Zetterberg

      Affiliations

    • Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Göteborg University, Mölndal, Sweden
    • ,
  • Kaj Blennow

      Affiliations

    • Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Göteborg University, Mölndal, Sweden

References 

  1. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet. 2006;367:1262–1270
  2. Lansbury PT. Back to the future: the ’old-fashioned’ way to new medications for neurodegeneration. Nat Med. 2004;10(Suppl):S51–S57
  3. Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2003;2:605–613
  4. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer’s Disease: the Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19:109–116
  5. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, et al. Biological markers for therapeutic trials in Alzheimer’s disease: proceedings of the biological markers working group—NIA initiative on neuroimaging in Alzheimer’s disease. Neurobiol Aging. 2003;24:521–536
  6. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci. 2001;17:101–118
  7. Ikeda S, Yanagisawa N, Allsop D, Glenner GG. Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down’s syndrome brains. Lab Invest. 1989;61:133–137
  8. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322–325
  9. Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelsø C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001;47:1776–1781
  10. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF. Neurology. 1999;52:1555–1562
  11. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652–656
  12. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512–519
  13. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666–669
  14. Spillantini MG, Goedert M, Jakes R, Klug A. Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. Proc Natl Acad Sci U S A. 1990;87:3952–3956
  15. Hasegawa M. Biochemistry and molecular biology of tauopathies. Neuropathology. 2006;26:484–490
  16. Bürger née Buch K, Padberg F, Nolde T, Teipel SJ, Stübner S, Haslinger A, et al. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer’s disease compared with controls. Neurosci Lett. 1999;277:21–24
  17. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–1322
  18. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705–710
  19. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain. 2006;129:3035–3041
  20. Buerger K, Alafuzoff I, Ewers M, Pirttilä T, Zinkowski R, Hampel H. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer disease. Brain. 2007;130:e82
  21. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95–102
  22. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002;59:1267–1272
  23. Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, et al. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer’s disease. Eur J Neurol. 2007;14:168–173
  24. Mitchell A, Brindle N. CSF phosphorylated tau: does it constitute an accurate biological test for Alzheimer’s disease?. Int J Geriatr Psychiatry. 2003;18:407–411
  25. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59:627–629
  26. Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology. 2005;65:1502–1503
  27. Hampel H, Bürger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005;62:770–773
  28. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schröder J, Zinkowski RP, et al. Multicentre assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology. 2007;69:2205–2212
  29. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228–234
  30. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging. 2007;Jan 18; [Epub ahead of print]
  31. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007;64:718–726
  32. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006;27:394–401
  33. Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx. 2004;1:226–234
  34. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology. 2003;61:1185–1190
  35. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry. 2005;13:914–917
  36. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5:655–660
  37. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354–362
  38. Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, et al. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer’s disease. Biochem Biophys Res Commun. 1999;257:787–791
  39. Zetterberg H, Blennow K. Plasma Abeta in Alzheimer’s disease: up or down?. Lancet Neurol. 2006;5:638–639
  40. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 2001;304:102–106
  41. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245–258
  42. Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC. Plasma Abeta levels do not reflect brain Abeta levels. J Neuropathol Exp Neurol. 2007;66:264–271
  43. Jack CR, Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397–1403
  44. Wang PN, Lirng JF, Lin KN, Chang FC, Liu HC. Prediction of Alzheimer’s disease in mild cognitive impairment: a prospective study in Taiwan. Neurobiol (Aging). 2006;27:1797–1806
  45. Ewers M, Teipel SJ, Dietrich O, Schönberg SO, Jessen F, Heun R, et al. Multicenter assessment of reliability of cranial MRI. Neurobiol Aging. 2006;27:1051–1059
  46. Jack CR, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. Neurology. 1998;51:993–999
  47. Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ, Soininen H. Hippocampus in Alzheimer’s disease: a 3-year follow-up MRI study. Biol Psychiatry. 2000;47:557–561
  48. Raz N, Rodrigue KM, Head D, Kennedy KM, Acker JD. Differential aging of the medial temporal lobe: a study of a five-year change. Neurology. 2004;62:433–438
  49. Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D, et al. Preclinical detection of Alzheimer’s disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage. 2005;25:783–792
  50. Hsu YY, Schuff N, Du AT, Mark K, Zhu X, Hardin D, et al. Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. J Magn Reson Imaging. 2002;16:305–310
  51. Krasuski JS, Alexander GE, Horwitz B, Daly EM, Murphy DG, Rapoport SI, et al. Volumes of medial temporal lobe structures in patients with Alzheimer’s disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry. 1998;43:60–68
  52. Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hänninen T, Laakso MP, et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging. 2004;25:303–310
  53. Teipel SJ, Pruessner JC, Faltraco F, Born C, Rocha-Unold M, Evans A, et al. Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. J Neurol. 2006;253:794–800
  54. Xu Y, Jack CR, O’Brien PC, Kokmen E, Smith GE, Ivnik RJ, et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology. 2000;54:1760–1767
  55. Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2001;71:441–447
  56. Ashburner J, Friston KJ. Voxel-based morphometry: the methods. Neuroimage. 2000;11:805–821
  57. Baron JC, Chételat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer’s disease. Neuroimage. 2001;14:298–309
  58. Busatto GF, Garrido GE, Almeida OP, Castro CC, Camargo CH, Cid CG, et al. A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer’s disease. Neurobiol Aging. 2003;24:221–231
  59. Chételat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. NeuroReport. 2002;13:1939–1943
  60. Pennanen C, Testa C, Laakso MP, Hallikainen M, Helkala EL, Hänninen T, et al. A voxel based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2005;76:11–14
  61. Teipel SJ, Alexander GE, Schapiro MB, Möller HJ, Rapoport SI, Hampel H. Age-related cortical grey matter reductions in non-demented Down’s syndrome adults determined by MRI with voxel-based morphometry. Brain. 2004;127:811–824
  62. Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer’s disease. Behavior Genetics. 2006;36:405–415
  63. Chételat G, Landeau B, Eustache F, Mézenge F, Viader F, de la Sayette V, et al. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage. 2005;27:934–946
  64. Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer’s disease. Neuroimage. 2004;23:708–716
  65. Teipel SJ, Born C, Ewers M, Bokde AL, Reiser MF, Möller HJ, et al. Multivariate deformation-based analysis of brain atrophy to predict Alzheimer’s disease in mild cognitive impairment. Neuroimage. 2007;38:13–24
  66. Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC. Focal decline of cortical thickness in Alzheimer’s disease identified by computational neuroanatomy. Cereb Cortex. 2005;15:995–1001
  67. Lerch JP, Pruessner J, Zijdenbos AP, Collins DL, Teipel SJ, Hampel H, et al. Automated cortical thickness measurements from MRI can accurately separate Alzheimer’s patients from normal elderly controls. Neurobiol Aging. 2008;23–30
  68. Heinsen H, Hampel H, Teipel S. Computer-assisted 3D reconstruction of the Nucleus basalis complex, including the Nucleus subputaminalis. Brain. 2006;129:E43
  69. Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO, Stöckel S, et al. Measurement of basal forebrain atrophy in Alzheimer’s disease using MRI. Brain. 2005;128:2626–2644
  70. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer’s disease: an independent component analysis. J Neurosci. 2006;26:10222–10231
  71. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637–4642
  72. Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer’s disease: an fMRI study. Hum Brain Mapp. 2005;26:231–239
  73. Bokde AL, Lopez-Bayo P, Meindl T, Pechler S, Born C, Faltraco F, et al. Functional connectivity of the fusiform gyrus during a face matching task in subjects with mild cognitive impairment. Brain. 2006;129:1113–1124
  74. Horwitz B, Warner B, Fitzer J, Tagamets MA, Husain FT, Long TW. Investigating the neural basis for functional and effective connectivity: application to fMRI. Philos Trans R Soc Lond B Biol Sci. 2005;360:1093–1108
  75. Teipel SJ, Bokde AL, Born C, Meindl T, Reiser M, Möller HJ, et al. Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. Brain. 2007;130:1745–1758
  76. Stahl R, Dietrich O, Teipel SJ, Hampel H, Reiser MF, Schoenberg SO. White matter damage in Alzheimer’s disease and in mild cognitive impairment: assessment with diffusion tensor MRI using parallel imaging techniques. Radiology. 2007;243:483–492
  77. Sydykova D, Stahl R, Dietrich O, Ewers M, Reiser MF, Schoenberg SO, et al. Fiber connections between the cerebral cortex and the corpus callosum in Alzheimer’s disease: a diffusion tensor imaging and voxel-based morphometry study. Cereb Cortex. 2007;17:2276–2282
  78. Teipel SJ, Stahl R, Dietrich O, Schoenberg SO, Perneczky R, Bokde AL, et al. Multivariate network analysis of fiber tract integrity in Alzheimer’s disease. Neuroimage. 2007;34:985–995
  79. Kuwert T, Bartenstein P, Grünwald F, Herholz K, Larisch R, Sabri O, et al. Klinische Wertigkeit der Positronen-Emissions-Tomographie in der Neuromedizin: Positionspapier zu den Ergebnissen einer interdisziplinären Konsensuskonferenz [Clinical significance of positron emission tomography in neuromedicine: a position paper on the results of an interdisciplinary consensus conference]. Nervenarzt. 1998;69:1045–1060
  80. Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res. 2006;3:161–170
  81. Minoshima S. Imaging Alzheimer’s disease: clinical applications. Neuroimaging Clin (N Am). 2003;13:769–780
  82. Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer’s disease. Int J Neuropsychopharmacol. 2001;4:223–230
  83. Teipel SJ, Drzezga A, Bartenstein P, Möller HJ, Schwaiger M, Hampel H. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer’s disease: a double-blind cross-over trial. Psychopharmacology (Berl). 2006;187:86–94
  84. Eckelman WC. Imaging of muscarinic receptors in the central nervous system. Curr Pharm Des. 2006;12:3901–3913
  85. Herholz K, Weisenbach S, Zündorf G, Lenz O, Schröder H, Bauer B, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage. 2004;21:136–143
  86. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Koeppe RA, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2005;76:315–319
  87. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–319
  88. Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging. 2007;July 21; [Epub ahead of print]
  89. Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging. 2007;28:1070–1074
  90. de Jong D, Jansen RW, Kremer BP, Verbeek MM. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci. 2006;61:755–758
  91. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, et al. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol. 2003;54:263–267
  92. Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem. 2007;101:1053–1059
  93. Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, et al. An Alzheimer’s disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett. 2006;409:215–219
  94. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343–349
  95. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Differentiation of Alzheimer’s disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol. 2005;191(Suppl 1):S95–S103
  96. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563–1572

PII: S1552-5260(07)00617-6

doi: 10.1016/j.jalz.2007.08.006

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1 , Pages 38-48 , January 2008

Article Tools

* Image Usage & Resolution